IRIS - Res&Arch Institutional Research Information System - Research & Archive

GAETANI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 982
EU - Europa 564
AS - Asia 187
AF - Africa 4
SA - Sud America 3
Totale 1.740
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 981
IE - Irlanda 213
IT - Italia 155
HK - Hong Kong 144
SE - Svezia 59
CN - Cina 27
FI - Finlandia 25
RU - Federazione Russa 20
RO - Romania 17
DE - Germania 15
BE - Belgio 12
FR - Francia 12
UA - Ucraina 10
GB - Regno Unito 9
JP - Giappone 5
VN - Vietnam 5
EG - Egitto 4
GR - Grecia 4
AT - Austria 3
NL - Olanda 3
CO - Colombia 2
CZ - Repubblica Ceca 2
PL - Polonia 2
UZ - Uzbekistan 2
BR - Brasile 1
CA - Canada 1
CH - Svizzera 1
ES - Italia 1
LB - Libano 1
SG - Singapore 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
TW - Taiwan 1
Totale 1.740
Salva come PNG Salva come JPEG
Città #
Chandler 254
Dublin 213
Hong Kong 144
San Mateo 65
Altamura 59
Perugia 59
Des Moines 42
Lawrence 39
Medford 39
Princeton 39
Andover 38
Ann Arbor 38
Wilmington 34
Ashburn 33
Beijing 25
Redmond 24
Redwood City 18
Helsinki 16
Falls Church 13
Brussels 12
Timisoara 10
Houston 9
Fairfield 7
Bucharest 6
Norwalk 6
Saint Petersburg 6
Seattle 6
Dong Ket 5
Rome 5
Tokyo 5
Woodbridge 5
Chicago 4
Milan 4
Giza 3
Lappeenranta 3
Moscow 3
Amsterdam 2
Boardman 2
Bogotá 2
Brixen 2
Cambridge 2
Foligno 2
Jacksonville 2
New York 2
San Paolo di Civitate 2
Turin 2
Vienna 2
Baltimore 1
Bollebygd 1
Böblingen 1
Chiaravalle 1
Dearborn 1
Florence 1
Frankfurt am Main 1
Fremont 1
Groningen 1
Hsinchu 1
Izmir 1
Madrid 1
Mogi Guacu 1
Monselice 1
Montreuil 1
Nanjing 1
Napoli 1
Parma 1
Radeberg 1
Secaucus 1
Shibin al Kawm 1
Tappahannock 1
Tulsa 1
Vancouver 1
Wuhan 1
Totale 1.338
Salva come PNG Salva come JPEG
Nome #
CSF and blood biomarkers for Parkinson's disease 111
Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis 87
Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis 71
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 63
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation 60
Visual pathway involvement in multiple sclerosis: Look straight in the eyes 55
Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis 52
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 52
2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes 51
Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency 44
Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis 44
Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes 43
Molecular profiling in Parkinsonian syndromes: CSF biomarkers 43
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation 42
Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature 42
Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis 41
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica 38
High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline 38
Serum neurofilament light chain as a preclinical marker of neurodegeneration 37
The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. 37
Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain 37
Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers 36
Infliximab monotherapy for neuro-Behçet's disease: a case report 34
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion 33
A blood test for Alzheimer's disease: a step forward 32
Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis 31
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease 30
Neurofilament light chain as a biomarker in neurological disorders 30
Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease 29
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 28
Synaptic dysfunction in multiple sclerosis: A red thread from inflammation to network disconnection 28
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 28
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI 28
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis 28
Finding a way to preserve mitochondria: New pathogenic pathways in experimental multiple sclerosis 27
High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease 27
Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms 27
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction 23
Blood biomarkers may distinguish among dementia disorders 21
Insights into the pathophysiology of psychiatric symptoms in central nervous system disorders: Implications for early and differential diagnosis 21
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 21
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 20
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 18
Impact of post-contrast MRI in the definition of active multiple sclerosis 17
Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use 15
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 15
Clinical correlates of state and trait anxiety in multiple sclerosis 12
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 9
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 9
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 9
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD 9
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 9
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 8
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 7
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 7
Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents 7
SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis 5
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 5
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis – a multicentre study 5
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 5
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 5
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 5
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 3
Hippocampal neuroplasticity and inflammation: Relevance for multiple sclerosis 2
Totale 1.856
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.041
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.041
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20196 0 0 0 0 0 0 0 0 0 3 3 0
2019/2020115 3 1 0 3 2 2 1 15 7 22 21 38
2020/2021157 3 4 4 1 72 17 7 20 11 5 6 7
2021/2022372 3 46 12 12 25 10 5 91 17 46 61 44
2022/2023843 44 184 15 67 62 102 4 36 294 1 25 9
2023/2024302 24 53 15 11 7 2 95 20 68 7 0 0
Totale 1.856